|Chemical and physical data|
|Molar mass||691.03 g·mol−1|
|3D model (JSmol)|
BMS-955176 is an experimental second generation HIV maturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells. First generation maturation inhibitors such as bevirimat were ineffective against some naturally occurring changes (polymorphisms) in the Gag protease polyprotein; BMS-955176 has been selected to better tolerate gag polymorphisms.
Results of a phase 2a trial of BMS-955176 was reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI). Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms. Phase 2b studies are currently ongoing in early 2016. It appears that development of BMS-955176 has been terminated.
- "BMS Maturation Inhibitor Is Potent Against HIV in Early Trial". 25 February 2015. Archived from the original on 23 July 2015. Retrieved 22 July 2015.
- "CROI2015: New HIV maturation inhibitor BMS-955176 appears more potent than earlier beviramat - Project Inform".
- Wang D, Lu W, Li F (November 2015). "Pharmacological intervention of HIV-1 maturation". Acta Pharmaceutica Sinica B. 5 (6): 493–9. doi:10.1016/j.apsb.2015.05.004. PMC 4675807. PMID 26713265.
- "Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor | CROI Conference". www.croiconference.org. Retrieved 2016-01-01.
- "HIV maturation inhibitor BMS-955176 looks promising in early study". www.aidsmap.com. Retrieved 2016-01-01.
- "Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2016-01-01.
- Clinical trial number NCT02386098 for "Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults" at ClinicalTrials.gov
- "GSK Discontinues Development of Maturation Inhibitor BMS-955176".